Conversion from Twice- to Once-daily Tacrolimus in Pediatric Kidney Recipients: A Pharmacokinetic and Bioequivalence Study

The objectives of this study were to investigate pharmacokinetic and pharmacogenetic parameters during the conversion on a 1:1 (mg:mg) basis from a twice-daily (Prograf) to once-daily (Advagraf) tacrolimus formulation in pediatric kidney transplant recipients.

Twenty-four-hour pharmacokinetic profiles were analyzed before and after conversion in 19 stable renal transplant recipients (age 7–19 years). Tacrolimus pharmacokinetic parameters [area under the concentration-time curve (AUC0–24), minimum whole-blood concentration (Cmin), maximum whole-blood concentration (Cmax), and time to achieve maximum whole-blood concentration (tmax)] were compared between Tac formulations and between CYP3A5 and MDR1 genotypes after dose normalization.

Author(s): Anne-Laure Lapeyraque, Nastya Kassir, Yves Théorêt, Maja Krajinovic, Marie-José Clermont, Catherine Litalien, Véronique Phan

Year: June 1, 2014